Compare Goodyear Tire & Rubber Co (GT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Merck & Co., Inc. — how do they compare? Goodyear Tire & Rubber Co trades at $7.2 (market cap $1.94B), while Merck & Co., Inc. trades at $128.04 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 157.4× Goodyear Tire & Rubber Co's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| GT | MRK | |
|---|---|---|
Market Cap | $1.94B | $305.29B |
Sector | Consumer Cyclical | Health |
52-Week High | $11.54 | $129.52 |
52-Week Low | $5.58 | $77.60 |
Enterprise Value | $9.25B | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GT trades at $7.18, up 7.81% today, with a bullish technical signal and moving average alignment. The stock shows attractive valuation ratios (P/E 4.69, P/B 0.64) but faces profitability challenges, with a net income margin of -11.64% in 2025. Recent news includes a shift to the S&P SmallCap 600 and a $1.05 billion senior notes offering. Q1 2026 earnings beat estimates, yet revenue trends are declining.
Outlook: Deep value metrics and analyst consensus target of $8.75 suggest upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Investors should weigh low valuation against operational headwinds and macroeconomic sensitivity.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
